MD Anderson Cancer Center, GI Medical Oncology Dept
Welcome,         Profile    Billing    Logout  
 7 Trials 
20 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Overman, Michael
NCT05961709: The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Recruiting
2
50
US
Cemiplimab
M.D. Anderson Cancer Center, Regeneron Pharmaceuticals
Colon Cancer
04/26
04/28
TWINPEAK, NCT05482893: PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the Study)

Recruiting
1/2
114
US
PT886, Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
12/25
04/26
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Recruiting
1/2
115
Europe, Canada, US
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab
Nouscom SRL, Merck Sharp & Dohme LLC
Solid Tumor, Adult
03/25
07/26
Singh, Harshabad
TWINPEAK, NCT05482893: PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the Study)

Recruiting
1/2
114
US
PT886, Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
12/25
04/26
NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
313
US
TAK-500, Pembrolizumab
Takeda
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
08/26
08/26
Henry, Jason
TWINPEAK, NCT05482893: PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the Study)

Recruiting
1/2
114
US
PT886, Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
12/25
04/26
NCT06208124: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Recruiting
1/2
240
US
IMM-6-415
Immuneering Corporation
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
06/27
07/27
NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
NCT05652686: A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Recruiting
1/2
61
US
PT217
Phanes Therapeutics
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
01/25
06/25
NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
313
US
TAK-500, Pembrolizumab
Takeda
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
08/26
08/26
INCLINE-101, NCT05399654: A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Recruiting
1/2
200
US, RoW
TAC-001
Tallac Therapeutics
Advanced or Metastatic Solid Tumors
01/26
05/26
NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
NCT05159700: A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Recruiting
1
46
US
PRJ1-3024
Zhuhai Yufan Biotechnologies Co., Ltd
Advanced Solid Tumor, Advanced Solid Malignancies
02/24
08/24
NCT06415487: ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Not yet recruiting
1
30
US
Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab
Acepodia Biotech, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
12/26
03/27
NCT05037149: Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Active, not recruiting
1
50
US
STP707, STP707 Powder for Injection
Sirnaomics
Solid Tumor
03/24
03/24
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Recruiting
1
430
Europe, Canada, US
SGN-B7H4V
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
06/25
01/27
NCT05669430: A Study of GV20-0251 in Patients With Solid Tumor Malignancies

Recruiting
1
268
US
GV20-0251
GV20 Therapeutics
Solid Tumor, Adult, Refractory Cancer, Bladder Urothelial Carcinoma, Cholangiocarcinoma, Adenocarcinoma of the Colon, Endometrial Carcinoma, Head and Neck Carcinoma, Cutaneous Melanoma, Non-small Cell Lung Cancer, Adenocarcinoma of the Rectum
12/25
06/26
SGNBB228-001, NCT05571839: A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
SGN-BB228
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
10/25
09/28
NCT05848739: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Recruiting
1
115
US
ST316, FOLFIRI regimen & bevacizumab, FOLFIRI, Fruquintinib
Sapience Therapeutics
Breast Cancer Metastatic, Pancreatic Cancer, NSCLC, Metastatic, Synovial Sarcoma, Colon Cancer, Metastatic Colon Cancer, Melanoma Recurrent, Metastatic Skin Cancer, Melanoma Stage IV, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Cholangiocarcinoma, Ovarian Cancer, Metastatic Melanoma, Hepatocellular Carcinoma
05/26
05/27
NCT05377528: Study of AGEN1571 in Participants With Advanced Solid Tumors

Active, not recruiting
1
22
US
AGEN1571, Balstilimab, AGEN2034, Botensilimab, AGEN1181
Agenus Inc.
Advanced Solid Tumor
01/27
01/27

Download Options